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in Comparison to Two Other Molecular Assays within a
Multihospital Health Care Center
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Clostridioides difﬁcile infection (CDI) remain a serious issue in the United
States. Fast and accurate diagnosis of CDI is paramount to achieve immediate infection control initiation, triaging, and isolation, as well as appropriate antibiotic treatment. However, both, over- and underdiagnosis can lead to adverse patient outcomes, such as unnecessary administration of antibiotics or unwanted spread of
spores in any hospital setting, respectively. In this prospective study, we evaluated
the FDA-cleared Aries C. difﬁcile assay and compared its performance and workﬂow
characteristics to those of the BD Max Cdiff and Xpert C. difﬁcile/Epi assays. Out of
302 samples tested, 55 (18.2%) samples were positive, and 234 (77.5%) samples were
negative for C. difﬁcile by all three testing methods. Comparison results showed a positive and negative percent agreement (PPA and NPA, respectively) between the Aries
and Xpert assays of 95.2% (59/62) and 99.2% (238/240), respectively. The PPA and
NPA between the Aries and BD Max assays were 91.8% (56/61) and 96.6% (230/238),
respectively. Invalid result rates were determined to be 2.6% for the BD Max assay,
1.0% for the Aries assay, and 0% for the Xpert assay. Hands-on time (HoT) and total
turnaround time (TAT) varied considerably depending on the sample number and
instrument throughput. The HoT ranged from 1.2 to 3.5 min per sample, and the
TAT was 1 to 2.3 h. Overall, the results demonstrated that the Aries assay is a rapid
and sensitive method for the diagnosis of CDI in clinical laboratories.
ABSTRACT
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C

lostridioides difﬁcile is an anaerobic, fastidious, spore-forming, Gram-positive bacillus that causes hospital-acquired diarrhea and antibiotic-associated pseudomembranous colitis. The bacterium produces harmful exotoxins, toxin A (TcdA) and toxin B
(TcdB), that damage the colonic mucosa and are associated with a more severe form of
the disease. According to the Centers for Disease Control and Prevention (CDC), C.
difﬁcile infection (CDI) is one of the most common hospital-acquired infections and is
responsible for approximately 15,000 deaths annually in the United States. (https://
www.cdc.gov/hai/organisms/cdiff/cdiff_infect.html). It has been estimated that CDIassociated hospital stays have increased by 9.2% between 2011 and 2015, and the
average cost per case for hospital-onset CDI is about $34,157, which is 1.5 times the
cost of community-onset CDI (1, 2). The clinical signs and symptoms presented by CDI
are highly nonspeciﬁc, such as mild to moderate diarrhea, nausea, and abdominal
cramps, and therefore, it is difﬁcult to distinguish between patients with and without
CDI (3). Several testing methods are currently available for the diagnosis of CDI, such as
stool and toxigenic culture, cell cytotoxicity neutralization assays (CCNAs), glutamate
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dehydrogenase (GDH) assays, toxin detection by enzyme immunoassays (EIAs), and
toxin gene detection by nucleic acid ampliﬁcation tests (NAATs).
NAATs for the detection of C. difﬁcile have rapidly evolved over the years, and currently,
more than a dozen U.S. Food and Drug Administration (FDA)-approved NAATs are commercially available (https://www.fda.gov/medical-devices/vitro-diagnostics/nucleic-acid
-based-tests). Most of these assays detect both the tcdA and tcdB genes for their
corresponding toxins or the tcdB gene for TcdB only. Recent investigations show that
TcdB is a more virulent toxin than TcdA in several cell types; however, the detection of
both tcdA and tcdB may be important, as the individual contributions of the toxins in
CDI pathogenesis remain ambiguous (4, 5).
The Aries C. difﬁcile assay (Luminex Corporation, Austin, TX) is an automated NAAT
for the qualitative detection of the tcdA and tcdB genes from stool samples from
patients suspected of having CDI. The assay uses Luminex Corporation’s MultiCode
chemistry in combination with the Luminex Aries system, an automated platform that
performs nucleic acid extraction and puriﬁcation, real-time PCR for the detection of
target-speciﬁc DNA, and data analysis. The aim of this study was to evaluate the
performance characteristics and workﬂow of the Aries C. difﬁcile assay compared to
those of the Xpert C. difﬁcile/Epi (Cepheid, Sunnyvale, CA) and the BD Max Cdiff (Becton,
Dickinson, Franklin Lakes, NJ) assays using deidentiﬁed, remnant stool samples.
(This study was presented in part at the 2018 American Society of Microbiology
Annual Meeting in Atlanta, GA.)
MATERIALS AND METHODS
Samples. A total of 302 selected deidentiﬁed remnant stool samples in Cary-Blair medium submitted
for routine clinical testing by the Xpert assay were included in the study. Samples tested by the Xpert
assay were deidentiﬁed and renumbered to mask the identity of the subject to the operators and
investigator. The comparator method’s result prior to study testing was not known to the operators.
Study design. This prospective comparison study was performed at Northwell Health Laboratories
(Lake Success, NY, USA) under an institutional review board (IRB)-approved protocol (Feinstein Institutes
for Medical Research; no. 17-08-269-03). Deidentiﬁed remnant stool samples submitted for routine
clinical testing by the Xpert assay were collected between 1 July and 15 October 2017. The samples were
subsequently tested by the Aries and the BD Max assays. Any disagreement between all three NAATs was
further investigated by toxin gene sequencing.
Molecular testing. All assays were performed according to the individual manufacturer’s instructions. For the Aries assay, unpreserved, raw stool samples were preprocessed using the Aries stool
resuspension kit. Eight hundred microliters of Aries stool resuspension buffer was added to a 2-ml Aries
stool resuspension tube. The primary stool sample (⬃160 l) was added using the Aries stool resuspension swab. The tube was vortexed for 15 s and centrifuged at 2,000 ⫻ g for 30 s. A total of 200 l of the
preprocessed stool was pipetted into the sample chamber of the Aries C. difﬁcile assay cassette. The
cassette was then placed into an Aries magazine, which was inserted into an Aries system. Internal
scanning automatically associates the preloaded Aries C. difﬁcile assay program with the cassette. Once
the run is initiated, nucleic acid from the sample is extracted, puriﬁed, and ampliﬁed automatically within
the Aries system and the C. difﬁcile assay cassette. The total assay time, including extraction and PCR
cycling, is approximately 2 h. Following completion, the results were reported as either toxigenic C.
difﬁcile positive, negative, or invalid. None of the samples underwent a freeze-thaw cycle, and all samples
remaining after testing were frozen at less than –70°C for discordant analysis and/or conﬁrmatory testing
as needed.
Discordant analysis. All samples that showed disagreement with any of the three NAATs were
further investigated using an alternative PCR with subsequent bidirectional sequencing. A 10-l loopful
(approximately 100 to 150 mg) of the stool sample was pretreated in 1 ml of easyMAG lysis buffer
(bioMérieux, Inc., Durham, NC), 850 l of the pretreated stool was extracted using the bioMérieux the
NucliSENS easyMAG system, and 5 l of the extracted nucleic acids was subjected to singleplex PCR.
Bidirectional sequencing was performed using M13-tagged forward and reverse primers that targeted
different regions of tcdA and tcdB than did the Aries C. difﬁcile assay. Following PCR, unincorporated
primers and deoxynucleoside triphosphates (dNTPs) were removed by treatment with exonuclease I and
shrimp alkaline phosphatase (Thermo Fisher Scientiﬁc, Waltham, MA). The BigDye Terminator v3.1 cycle
sequencing kit (Thermo Fisher) was used to perform dye-labeled terminator cycle sequencing with
detection on the 3730xl analyzer (Thermo Fisher). BLAST analysis (NCBI) was conducted for sequences
that were at least 200 bases in length, had a Phred score greater than or equal to 20 for at least 90% of
the bases, and contained fewer than 5% ambiguous base calls. Sequences with greater than 95% query
coverage and identity and an expected value (E value) of less than 10⫺30 compared to the reference
sequence were considered positive. A weak-positive result may be obtained if the sequence that was
generated was speciﬁc to the target but was only 100 to 199 nucleotides or was only detected in one
direction.
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TABLE 1 Analysis of test results for all samples using the Aries, Xpert, and BD Max assays
Result by assay
Sample
55
4
2
2
1
3
1
234

Aries
⫹
⫹
⫹
⫺
⫺
⫺
⫺
⫺

Xpert
⫹
⫹
⫺
⫹
⫹
⫺
⫺
⫺

BD Max
⫹
⫺
⫺
⫺
⫹
Invalida
Not determinedb
⫺

aThese
bThis

specimens remained invalid after repeat testing.
specimen was invalid on initial testing and was not retested.

Time and motion analysis. Workﬂow analysis of the Xpert, BD Max, and Aries assays was conducted
on a single day. The workﬂow analysis was performed for different run sizes (one, six, and 12 samples)
to mimic potential different work processes and volumes at other institutions. The following parameters
were included: (i) hands-on time (HoT), including manual steps such as sample setup, initiation of the
instrument, postrun tasks, and result reporting; and (ii) total turnaround time (TAT), including HoT and
hands-off or automation time (AuT). The times required for the different phases of the assay were
recorded by two observers independent of performing the assay. All assays were performed by
experienced medical technologists who were familiar with the instruments and had prior training on the
assay procedures.
Statistical analysis. The results were analyzed to determine the positive percent agreement (PPA)
(no. of true positives/[no. of true positives ⫹ no. of false negatives]), negative percent agreement (NPA)
(no. of true negatives/[no. of true negatives ⫹ no. of false positives]), and the overall percent agreement
for Aries with each of the comparator platforms. True positivity/negativity was determined as two of
three positives/negatives by any assay. Ninety-ﬁve percent conﬁdence intervals (CIs), including continuity
corrections, were calculated according to the procedure described by Newcombe (6) and outlined by
Wilson (7).

RESULTS
Analytical performance. Of the 302 samples included in this study, 55 (18.2%)
samples were positive, and 234 (77.5%) samples were negative for C. difﬁcile by all three
assays. A total of 62 (20.5%) samples were positive by the Xpert assay, 61 (20.2%)
samples were positive by the Aries assay, and 56 (18.5%) samples were positive by the
BD Max assay (Table 1). The PPA, NPA, and overall agreement between the Aries and
Xpert assays were 95.2% (59/62; 95% CI, 85.6% to 98.7%), 99.2% (238/240; 95% CI,
96.7% to 99.9%), and 98.3% (297/302), respectively (Table 2). The PPA, NPA, and overall
agreement between the Aries and BD Max assays were 98.2% (55/56; 95% CI, 89.2% to
99.9%), 97.5% (236/242; 95% CI, 94.4% to 98.9%), and 97.7% (291/298), respectively
(Table 3).
Comparison of the BD Max and Xpert assays revealed an overall agreement of 98.0%
(292/298; 95% CI, 95.7% to 99.3%) and PPA and NPA of 90.3% (56/62; 95% CI, 79.5% to
96.0%) and 100.0% (236/236; 95% CI, 98.0% to 100.0%), respectively.
Eight (2.6%) samples yielded invalid results on the initial run by the BD Max assay.
Seven of these samples were available for retesting, and four of them generated a valid
negative result upon repeat testing. Three (1%) invalid results were obtained by the
Aries assay; however, upon retesting, valid negative results were obtained. No samples
yielded an invalid result with the Xpert assay.

TABLE 2 Performance characteristics of the Aries assay compared to the Xpert assay
No. with Xpert result ofa:
Aries result
Positive
Negative

Positive
59
3

Negative
2
238

Total no. of samples
61
241

Total

62

240

302

aThe

PPA and NPA were 95.2% (95% conﬁdence interval [CI], 85.6% to 98.7%) and 99.2% (96.7% to 99.9%),
respectively.
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TABLE 3 Performance characteristics of the Aries assay compared to the BD Max assay
No. with BD Max result ofa:
Aries assay result
Positive
Negative

Positive
55
1

Negative
6
236

Total no. of samples
61
237

Total

56

242

298b

aThe

PPA and NPA were 98.2% (95% CI, 89.2% to 99.9%) and 97.5% (94.4% to 98.9%), respectively.
bFour samples generated invalid results by the BD Max assay. Three of these samples remained invalid after
repeat testing. One sample was not further tested. All four samples tested negative by the Aries and Xpert
assays.

Discordant analysis. A total of 13 (4.3%) samples yielded discrepant results
where the three NAATs were not in agreement. One sample was not further tested
and was eliminated from the discordant analysis. The dispositions of the 12
remaining discordant samples and analysis are shown in Table 4. Three samples
tested negative by both the Aries and Xpert assays but produced an invalid result
with BD Max assay even after retesting. Two of these samples were also negative by
bidirectional sequencing, and one sample produced a weak-positive sequencing
result for tcdA. A sequencing result was considered weak positive when the
sequence generated was speciﬁc to the target but was only 100 to 199 nucleotides
or was only detected in one direction. Two samples tested negative by both the
Aries and BD Max assays but generated a positive result with the Xpert assay and
bidirectional sequencing. One specimen tested positive by both the Xpert and BD
Max assays but generated a negative result with the Aries assay (Aries false
negative). This specimen was also positive by bidirectional sequencing. Two specimens were negative by both the Xpert and BD Max assays but generated a positive
result for tcdB by the Aries assay. Upon sequencing, only one of these two
specimens was conﬁrmed as tcdB positive. Finally, four samples tested positive with
the Aries and Xpert assays but generated negative results with the BD Max assay.
Three of these samples were also positive by bidirectional sequencing.
Time and motion data. The TAT and HoT varied depending on sample number and
instrument throughput. The total HoT for testing one sample was less than 4 min
(range, 0:01:59 to 0:03:30 h:min:s) for all three assays (Fig. 1). The HoT for testing one
sample was lowest for the BD Max assay (0:01:59 h:min:s) and was highest for the Aries
assay (0:03:30 h:min:s). However, as the number of samples increased to six and 12, the
Xpert assay required the highest total HoT (0:14:43 and 0:28:20 h:min:s, respectively),
whereas those for the Aries assay were 0:10:51 and 0:20:08 h:min:s, and the BD Max
assay was fastest at 0:7:33 and 0:14:15 h:min:s, respectively. The total TAT for testing
one, six, and 12 samples was highest for the Aries assay (2:00:51, 2:08:29, and 2:18:07

TABLE 4 Results of discordant analysis for discrepant samples
Result (gene[s]) by assay or method
a

Sample ID
65
158
72
109
266
273
209
243
226
82
117
207
aID,

Aries
⫺
⫺
⫺
⫺
⫺
⫺
⫹ (tcdB)
⫹ (tcdB)
⫹ (tcdA, tcdB)
⫹ (tcdB)
⫹ (tcdB)
⫹ (tcdA)

Xpert
⫺
⫺
⫺
⫹
⫹
⫹
⫺
⫺
⫹
⫹
⫹
⫹

BD Max
Invalid
Invalid
Invalid
⫺
⫺
⫹
⫺
⫺
⫺
⫺
⫺
⫺

Bidirectional sequencing
⫺
⫺
⫹ (low positive, tcdA)
⫹ (tcdA, tcdB)
⫹ (tcdA, tcdB)
⫹ (tcdA, tcdB)
⫺
⫹ (tcdB)
⫺
⫹ (tcdA, tcdB)
⫹ (tcdB)
⫹ (tcdA, tcdB)

Final call
Negative
Negative
Negative
Positive
Positive
Positive
Negative
Positive
Positive
Positive
Positive
Positive

identiﬁer.
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FIG 1 Comparison of hands-on times (HoT) for C. difﬁcile test systems.

h:min:s, respectively) and lowest for the Xpert assay (0:59:22, 1:15:38, and 1:35:09
h:min:s, respectively), provided that sufﬁcient bays are installed in the Xpert instrument
(Fig. 2). The TAT for BD Max was in between, at 1:53:22, 1:59:24, and 2:07:03 h:min:s for
testing one, six, and 12 samples, respectively.

FIG 2 Comparison of total turnaround time (TAT) for C. difﬁcile test systems. The hands-on time (HoT) is shown in light-shaded bars, and the automation time
is shown in the dark-shaded bars.
November 2019 Volume 57 Issue 11 e01092-19
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DISCUSSION
In this study, we compared the performance and workﬂow characteristics of three
commercially available NAATs for C. difﬁcile detection, the Aries C. difﬁcile assay, the
Xpert C. difﬁcile/Epi assay, and the BD Max Cdiff assay. Three hundred two stool samples
were collected from patients suspected of having CDI, and 55 (18.2%) samples were
identiﬁed as positive for C. difﬁcile by all three molecular assays. Analytical results
demonstrated that all three molecular assays had comparable sensitivity and speciﬁcity
(⬎91% PPA and ⬎98% NPA) and were in agreement for 289 (95.7%) of the samples. All
three molecular platforms had a relatively low invalid result rate (⬍3%), and these
invalid rate data were in agreement with previous studies (8, 9).
Approximately 4% of the samples had discrepant results among the three molecular
methods. One specimen tested negative by both the Aries and Xpert assays and was
invalid on the BD Max assay but generated a positive result with bidirectional sequencing. However, the sequencing assay was weakly positive only for tcdA (1 of 2 replicates,
1 primer set only), indicating that the pathogen concentration might have been below
the limit of detection for the Aries assay. The Xpert assay can only detect tcdB and
therefore generated a negative result for this sample. Additionally, since the BD Max
assay was repeatedly invalid for this specimen, sample inhibition may have also
contributed to the discrepant results. Two samples tested positive by the Xpert assay
but generated a negative result by the Aries and BD Max assays. Bidirectional sequencing for these samples was also positive. However, the sequencing assay uses more of
the specimen than does the Aries assay, undergoes a separate off-board extraction, and
is performed in singleplex, which may account for a higher sensitivity. Differences in the
limits of detection (LODs) for the three assays might also be responsible for the
discrepancies in the test results. According to the analytical performance data described in the U.S. FDA 510(k) summaries for these assays, the reported LODs of the
Aries, BD Max, and Xpert assay are 5.10 CFU/cassette, 265 CFU/loop, and 460 CFU/swab,
respectively (https://www.accessdata.fda.gov/). This suggests that the Aries is the most
sensitive of the three assays, which could account for the Aries false-positive results.
However, all three assays are highly sensitive and show very similar performance
characteristics in this study.
Analysis of the time and motion data revealed that the BD Max assay has the lowest
HoT for testing one sample, followed by the Xpert and Aries assays. As the number of
samples increased to six and 12, the Xpert assay demonstrated the highest HoT,
followed by the Aries and BD Max assays. The TAT was lowest for the Xpert assay,
followed by the BD Max and Aries assays; however, TAT can differ considerably
depending on the number of systems, modules, or bays installed for each platform. The
Aries and BD Max systems include two bays or modules and can test 12 and 24 samples
at a time, respectively. The Xpert system is available in 1-, 2-, 4-, 16-, 48-, or 80-module
conﬁgurations, and therefore, the TAT could be considerable higher if fewer modules
are installed than can accommodate the sample load. For the BD Max assay, the higher
invalid result rate than those of the Aries and Xpert assays may further increase the TAT
if repeat testing is considered in the TAT calculations.
The diagnostic paradigm for C. difﬁcile has evolved and changed in recent years, but
the optimal diagnostic method for CDI is still a controversial subject (10). Diagnosis and
management of CDI are particularly challenging because of nonspeciﬁc clinical symptoms, high rates of asymptomatic colonization with both toxigenic and nontoxigenic
strains of C. difﬁcile, and the difﬁculties associated with identifying unstable exotoxin
(11). According to the diagnostic guidelines published by the European Society of
Clinical Microbiology and Infectious Diseases (ESCMID) and the Infectious Diseases
Society of America (IDSA), effective diagnosis of CDI requires both clinical presentation
of the symptoms and conﬁrmatory laboratory evidence of C. difﬁcile exotoxin- or
toxin-producing C. difﬁcile strains in stool samples (12, 13).
EIAs for toxins A and B are rapid and relatively inexpensive but have demonstrated
poor sensitivity (47% to 72%) compared to molecular tests (14, 15). Additionally, no
November 2019 Volume 57 Issue 11 e01092-19

jcm.asm.org 6

Evaluation of the Luminex Aries C. difﬁcile

Journal of Clinical Microbiology

correlation has been observed between the active stool toxins measured by EIAs and
disease severity in CDI (16). CCNAs and toxigenic cultures are more sensitive than EIAs;
however, these assays are labor-intensive and time-consuming and can have a turnaround time of up to 3 days (17). GDH assays have demonstrated ⬎90% sensitivity and
speciﬁcity compared to culture and are commonly used as a screening test (18). However,
since GDH is expressed by both toxigenic and nontoxigenic strains of C. difﬁcile, conﬁrmatory tests, such as NAATs or toxin assays, are required for positive results.
NAATs have demonstrated higher sensitivity than those of currently available toxin
assays (92.2% to 97.7% versus 42.3% to 82.8%, respectively), and the more rapid
diagnosis can positively impact patient care by decreasing empirical therapy among
patients without CDI from 13.6% to 5.6% (19, 20). Additionally, since NAATs can detect
more toxigenic C. difﬁcile cases, implementation of these assays can facilitate improved
infection control measures, thereby reducing the overall infection rate of the clinical
institution (21, 22). Although most clinical laboratories have shifted from toxin assays to
NAATs, the clinical utility of NAATs is still under debate for diagnosing CDI (10). Since
NAATs target the toxin genes regardless of toxin production, a NAAT positive result
does not always indicate clinical disease. Recent studies have demonstrated that relying
exclusively on NAATs for the diagnosis of CDI can result in overdiagnosis, overtreatment, and an increase in health care costs (23, 24). To address this problem, current
ESCMID guidelines recommend a multistep algorithm for diagnosing CDI that includes
conﬁrmation of a positive result by the ﬁrst diagnostic test by one or two other
conﬁrmatory tests or reference methods (12). However, the latest guidelines from the
IDSA recommend that NAATs be used as a standalone diagnostic test in cases where
there are preagreed institutional criteria for patient stool submission (13). Thus, as there
is a still lack of consensus regarding the best diagnostic method for CDI, clinical
laboratories should develop and optimize their own diagnostic algorithm based on
their patient population, CDI severity, and prevalence rate.
This study demonstrated that the Aries C. difﬁcile assay has performance and
workﬂow characteristics comparable to those of other established molecular CDI
diagnostic tests. The Aries assay also provides wider ﬂexibility with a unique mixture of
batched and “sample-to-answer” testing. It can be concluded that for the diagnosis of
CDI, NAATs, such as the Aries, Xpert, and BD Max assays, can provide highly sensitive
and speciﬁc results in a considerably shorter time than with other available nonmolecular methods. However, future studies evaluating the different diagnostic algorithms
involving NAATs are required to understand the complete potential of these assays in
CDI diagnosis.
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